Aptinyx to Present at Upcoming Virtual Investor Conferences
June 16 2020 - 8:37AM
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that company
management will be presenting at the following upcoming investor
conferences:
- 2020 BMO Prescription for Success
Healthcare Conference on Tuesday, June 23, 2020 at 2:30
p.m. ET and;
- SVB Leerink CybeRx Series: 2nd Annual CNS
Forum on Wednesday June 24, 2020 at 1:15 p.m. ET.
A live webcast of each presentation will be available on the
“Events and Presentations” page in the “Investors & Media”
section of Aptinyx’s website at https://ir.aptinyx.com. A
replay of the webcast will be archived on Aptinyx’s website for 30
days following the event.
About AptinyxAptinyx Inc. is a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of proprietary synthetic small molecules for
the treatment of brain and nervous system disorders. Aptinyx has a
platform for discovery of novel compounds that work through a
unique mechanism to modulate—rather than block or
over-activate—NMDA receptors and enhance synaptic plasticity, the
foundation of neural cell communication. The company has three
product candidates in clinical development in central nervous
system indications, including chronic pain, post-traumatic stress
disorder, and cognitive impairment associated with Parkinson’s
disease. Aptinyx is also advancing additional compounds from its
proprietary discovery platform, which continues to generate a rich
and diverse pipeline of small-molecule NMDA receptor modulators
with the potential to treat an array of neurologic disorders. For
more information, visit www.aptinyx.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the company’s business plans and
objectives, including therapeutic effects of the company’s product
candidates and discovery platform. Risks that contribute to the
uncertain nature of the forward-looking statements include: the
effect of COVID-19 on our business and financial results, including
with respect to disruptions to our clinical trials, business
operations, and ability to raise additional capital; the success,
cost, and timing of the company’s product candidate development
activities and planned clinical studies; the company’s ability to
execute on its strategy; the company’s estimates regarding
expenses, future revenue, and capital requirements; as well as
those risks and uncertainties set forth in the company’s most
recent annual report on Form 10-k and subsequent filings with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Investor and Media Contact:Nick SmithAptinyx
Inc.ir@aptinyx.com or corporate@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024